asa guidelines for glp 1 drugs GLP-1 RA guidance roundup Frontiers | Mechanisms of action

Asia-Pacific is the fastest-growing regional GLP-1 drug market at 22.6% CAGR , driven by rapidly rising obesity prevalence China now reports 18.6% adult obesity prevalence up from 7.1% in 2000 combined with expanding private health insurance and regulatory approvals

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B

Source The COVID-19 pandemic has had a positive effect on the market for Glucagon-like Peptide-1 (GLP-1) Agonists as people with diabetes and high blood sugar levels are more likely to become seriously ill or die if they catch COVID-19

Saxenda (Liraglutide) is a prescription medication used to aid weight management in adults with obesity

How GLP-1 Medication Supports Weight Loss GLP-1 medications help users lose weight by regulating hunger and metabolism